Holen Sie sich die Stockscreener-App
101.35
1.66%
-1.71
Handel nachbörslich:
101.35
Schlusskurs vom Vortag:
$103.06
Offen:
$103.17
24-Stunden-Volumen:
901.72K
Relative Volume:
0.96
Marktkapitalisierung:
$6.55B
Einnahmen:
$434.41M
Nettoeinkommen (Verlust:
$-128.05M
KGV:
-48.03
EPS:
-2.11
Netto-Cashflow:
$-250.52M
1W Leistung:
-0.15%
1M Leistung:
+14.55%
6M Leistung:
+5.16%
1J Leistung:
-4.71%
1-Tages-Spanne:
$100.57
$103.17
1-Wochen-Bereich:
$94.38
$103.17
52-Wochen-Spanne:
$73.04
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Firmenname
Blueprint Medicines Corp
Sektor
Branche
Telefon
617-374-7580
Adresse
45 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BPMC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
101.35 | 6.56B | 434.41M | -128.05M | -250.52M | -2.11 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-17 | Eingeleitet | Jefferies | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-05-06 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Bestätigt | Needham | Buy |
| 2023-07-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-11-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Eingeleitet | Berenberg | Buy |
| 2022-07-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-27 | Eingeleitet | Wells Fargo | Underweight |
| 2022-06-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-01 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Neutral |
| 2022-02-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Hochstufung | Stifel | Hold → Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Fortgesetzt | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-11-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-02 | Herabstufung | Jefferies | Buy → Hold |
| 2020-10-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Equal Weight |
| 2020-03-17 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-11-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-09-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-08-15 | Fortgesetzt | Raymond James | Mkt Perform |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Buy |
| 2019-04-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-09-25 | Eingeleitet | Leerink Partners | Outperform |
| 2017-12-11 | Bestätigt | Goldman | Buy |
Alle ansehen
Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten
Blueprint Medicines (BPMC) Stock Surges Over 6%, Breaching $100: What's Driving the Rally & What's Next? - Daily Chhattisgarh News
Blueprint Medicines’ SWOT analysis: stock’s potential in precision therapy market - Investing.com
Zacks Research Issues Positive Forecast for BPMC Earnings - Defense World
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp - GuruFocus
Gotham Asset Management LLC Makes New $309,000 Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery - Yahoo Finance
Investor Network: Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire
Dimensional Fund Advisors LP Has $3.51 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Shares Of Blueprint Medicines Corp (NASDAQ: BPMC): Are They Overvalued Compared To Others? - Stocksregister
Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus
Blueprint Medicines Executives Sell Shares - TradingView
Blueprint Medicines at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com
Amarin (NASDAQ:AMRN) & Blueprint Medicines (NASDAQ:BPMC) Financial Survey - Defense World
Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates - Yahoo Finance
Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript - Insider Monkey
Blueprint Medicines Corp (BPMC) Stock: A Year of Highs and Lows in the Market - investchronicle.com
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Med - GuruFocus
Blueprint Medicines Corp (BPMC) Performance and Fundamentals Dashboard tells a completely different story - Sete News
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Medicines | BPMC Stock News - GuruFocus
Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ... - Yahoo Finance
Blueprint Medicines reports Q1 EPS 1c, consensus (44c) - TipRanks
Blueprint Medicines Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Blueprint Medicines Q1 2025 beats EPS, stock rises - Investing.com India
Blueprint Medicines Corp. Reports Strong Earnings Growth - TipRanks
Blueprint Medicines (BPMC) Faces Q1 Revenue Miss, Focuses on Str - GuruFocus
Blueprint Medicines Corp Reports Q1 2025 Earnings: EPS of -$0.56 - GuruFocus
Earnings call transcript: Blueprint Medicines Q1 2025 beats EPS, stock rises By Investing.com - Investing.com South Africa
Blueprint Medicines Corp (NASDAQ: BPMC) Stock Jumping 14.80% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Predicting Blueprint Medicines Corp’s (BPMC) earnings for the current quarter - uspostnews.com
Blueprint Medicines Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Blueprint Medicines Q1 2025 slides: AYVAKIT revenue surges 61%, guidance raised - Investing.com India
Blueprint Medicines: Q1 Earnings Snapshot - marketscreener.com
Blueprint Medicines Corp earnings beat by $0.50, revenue fell short of estimates - Investing.com
Blueprint Medicines Reports First Quarter 2025 Results - TradingView
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
Blueprint Medicines' Q1 Earnings Decline, Revenue Increases - marketscreener.com
Blueprint Medicines patents new EGFR mutant inhibitors for NSCLC - BioWorld MedTech
Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $130.00 by Analysts at Needham & Company LLC - Defense World
Needham Adjusts Price Target for Blueprint Medicines (BPMC) Ahea - GuruFocus
What Analysts Are Saying About Blueprint Medicines Stock - Benzinga
Blueprint Medicines stock target cut to $130 at Needham - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Envestnet Asset Management Inc. Buys 3,723 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Announces Q1 2025 Earnings Date: Key Biotech Updates Coming May 1 - Stock Titan
Finanzdaten der Blueprint Medicines Corp-Aktie (BPMC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):